|
|
|
| Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma? |
| Hua-Yu Yang, Le-Jia Sun, Yi-Lei Mao∗ |
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China
∗ Corresponding author.
E-mail address: pumch-liver@hotmail.com (Y.-L. Mao). |
|
|
|
|
Abstract During the past decades, the treatment of hepatocellular carcinoma (HCC) has been limited to surgical resection and liver transplantation, but the prognosis is still poor. Recently, tumor immunotherapy, particularly immune checkpoints programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) blockade, brings a breakthrough for HCC [1,2]. However, anti-PD-1/PD-L1 immunotherapy is not satisfactory and the response rates were between 20% and 30% [3]. How to improve the efficacy of PD-1/PD-L1 blockade is the main issue.
|
|
|
|
|
|
|
null
|
|
|
|
2018, Vol. 17 
